Congenital Zika syndrome (CZS) is a major concern in India and highlights the multifaceted challenges posed by the Zika virus (ZIKV). The alarming increase in CZS cases in India, a condition that has serious effects on both public health and newborns, has raised concerns. This review highlights the importance of raising concern and awareness and taking preventive measures by studying the epidemiology, clinical symptoms, and potential long-term consequences of CZS. The review also contributes to worldwide research and information sharing to improve the understanding and prevention of CZS. As India deals with the changing nature of CZS, this thorough review is an important tool for policymakers, health workers, and researchers to understand what is happening now, plan for what to do in the future, and work together as a team, using medical knowledge, community involvement, and study projects to protect newborns’ health and reduce the public health impact of these syndromes.

Microbial keratitis is a serious disease of the cornea that poses a major risk to the health and vision of people all over the world. It is caused by various microbial invaders, including bacteria, fungi and viruses, making it difficult to diagnose and treat. Combating microbial keratitis requires understanding the intricate web of immune responses and pathogenic pathways that cause the infection. To develop innovative strategies to treat the disease and improve patient survival, we need to understand how the immune system works, how hosts and infections interact and how complicated the pathophysiology is. Looking to the future, we are on the cusp of a transformative era in treating microbial keratitis. Innovations in therapeutic technology, such as targeted antimicrobial drugs, immunomodulatory therapies and precision medicine techniques, are set to revolutionise the field. These advancements will enable customised treatments for specific microbiological causes and patient characteristics. Integrating molecular biology, imaging and artificial intelligence into novel diagnostic techniques will enhance early diagnosis and personalised treatment programmes, leading to better clinical outcomes and reduced ocular morbidity. Collaboration between clinicians, researchers, and industry representatives is critical to accelerating the translation of scientific knowledge into clinical practice. Improving patient care, increasing treatment efficacy and saving eyesight are the goals for the future of microbial keratitis treatment.

species, a subgroup of Actinomycetes bacteria, have been analysed for their antiviral properties. These bioactive secondary metabolites, which have a broad spectrum of chemical structures and strong biological activity, offer a promising opportunity for new antiviral therapeutics against various viral infections. These metabolites target different stages of viral replication or interactions with host cells, making them important for biological research and pharmaceutical development. bacteria contain numerous antiviral mechanisms that inhibit viral infections at different stages of the viral life cycle. and other actinomycetes can improve the health of people with viruses, and recent research suggests that combining with other bacterial species could improve overall health and regulate infections. This emphasises the importance of comprehensive approaches to combating viral infections and research into natural products. Further research into multispecies combinations of and other bacterial species is needed to fully utilise their therapeutic potential against viral diseases.

The COVID-19 pandemic brought to light a complex challenge: the occurrence of multiple microbial co-infections in affected individuals. In addition to the primary infection caused by the SARS-CoV-2 virus, patients often had to contend with secondary infections caused by bacteria, viruses, and fungi. This complicated interaction of pathogens has presented significant clinical, diagnostic, and therapeutic hurdles. It has been observed that co-infections can exacerbate disease severity and complicate treatment strategies, necessitating a more comprehensive approach to patient care. In addition, distinguishing between viral and bacterial/fungal coinfections based on clinical symptoms alone remains a difficult task, underscoring the need for advanced diagnostic tools. The emergence of coinfections has also heightened concerns about antimicrobial resistance due to the widespread use of antibiotics and antifungals, underscoring the importance of prudent antimicrobial stewardship. As the pandemic continues to evolve, understanding, diagnosing, and effectively managing these multiple microbial coinfections have become critical imperatives for healthcare systems and researchers worldwide. The present review illustrated the past occurrence of various microbial infections that co-existed with the COVID-19.

produces a variety of bioactive compounds that prevent fungal growth, including aflatoxins. Aflatoxigenic fungi ( and ) are being researched concerning spp. and can prevent the spread of aflatoxins-producing fungi. Aflatoxin-degrading enzymes, which can convert poisonous aflatoxins into less dangerous compounds, are also produced by spp. The processes through which these microorganisms can be used to reduce aflatoxins in food and agricultural systems are still the subject of active research. To evaluate the novelty of tetracycline against the biosynthesis of aflatoxin in aflatoxigenic fungi via computational approach. In this study, we performed molecular docking of polyketide synthase (Pks-A), an enzyme that initiates aflatoxin biosynthesis using tetracycline, using the online SeamDock server. Our results showed that tetracycline had a strong affinity for Pks-A in the binding pocket. The binding energy of tetracycline was -12.7 kcal/mol, indicating a strong binding affinity between the two molecules. Furthermore, the binding site was located in the active site, which is a conserved region in Pks-A and is essential for catalysing the formation of aflatoxin. The results of our docking study suggest that tetracycline may be an effective inhibitor of aflatoxin biosynthesis.

Noncoding RNAs, known as miRNAs, regulate gene expression. Most miRNAs are converted from DNA sequences into primary miRNAs, processed into precursors, and matured. Survival or virulence of species is targeted by RNAi antifungal treatment. Silencing these genes can reduce fungal proliferation and pathogenicity, thereby improving therapy. RNAi can be used to treat ; however, most research has been conducted in controlled laboratory or animal studies. The immune system neutralizes spores, so not everyone gets sick. Aspergillosis can range from moderate allergic reactions to invasive, life-threatening disease. MiRNAs have been studied in numerous diseases, but their role in immune responses to pulmonary and systemic fungal infections is still being discovered. During disease progression, fungal pathogens can alter signaling and expression of miRNAs in the genetic network. Future investigations on the biological purpose of miRNAs, previously assumed to be a consequence of miRNA synthesis, will illuminate the regulatory function of the miRNA network in plant innate immunity. MiRNAs and their intended targets present opportunities for novel pathogen-fighting strategies and technologies.